Related Experiment Video
Updated: Jun 19, 2026

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder
Published on: January 9, 2015
Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics-induced obsessive-compulsive
Jun Soo Kwon1, Yeon Ho Joo, Hee Jung Nam
1Department of Neuropsychiatry, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea.
Context:
Several studies have indicated that atypical antipsychotics (AAP) induce obsessive-compulsive (OC) symptoms. Research exploring the mechanism of this phenomenon, however, has been extremely limited. Considering the indirect evidence of genetic control and difficulties in developing animal models and performing gene expression studies, genetic association studies could be an important approach to understanding the molecular mechanism of AAP-induced OC symptoms. The glutamate transporter gene SLC1A1, which was recently reported to be associated with obsessive-compulsive disorder (OCD), is a promising candidate gene for susceptibility to AAP-induced OC symptoms.
Objective:
To determine whether polymorphisms in SLC1A1 are associated with AAP-induced OC symptoms in patients with schizophrenia.
Design:
A pharmacogenetic case-control association study.
Setting:
Outpatient schizophrenia clinics.
Patients:
Clinically stable patients with schizophrenia who were receiving AAP treatment (n = 94; OC group). The OC group consisted of 40 patients with AAP-induced OC symptoms, and the non-OC group consisted of 54 patients who had received AAP for more than 24 months without developing OC symptoms.
Main Outcome Measures:
Allele, genotype, and haplotype frequencies. The association was tested with a logistic regression model using age, sex, and medication type as covariates.
Results:
Trends of association were observed in rs2228622 and rs3780412 (nominal P = .01; adjusted permutation P = .07) for the dominant model that was the inheritance model that best fit our data. In the haplotype -based analysis, the A/C/G haplotype at rs2228622-rs3780413-rs3780412 showed a significant association with AAP-induced OC symptoms; this association withstood multiple test correction (nominal P = .01; adjusted permutation P = .04; odds ratio, 3.955; 95% confidence interval, 1.366-11.452, for dominant model).
Conclusions:
These results suggest that sequence variations in SLC1A1 are associated with susceptibility to AAP-induced OC symptoms. This is the first published pharmacogenetic study on this phenomenon and provides preliminary evidence of the involvement of glutamatergic neurotransmission in the pathogenesis of AAP-induced OC symptoms.
Insights
Genetic variations in the SLC1A1 gene are linked to atypical antipsychotic-induced obsessive-compulsive symptoms in schizophrenia patients. This study explores the genetic basis of these symptoms, offering insights into treatment mechanisms.
Area of Science:
- Neuroscience
- Pharmacogenetics
- Psychiatry
Background:
- Atypical antipsychotics (AAP) are known to induce obsessive-compulsive (OC) symptoms.
- The underlying mechanisms remain largely unexplored.
- Genetic association studies offer a viable approach to investigate the molecular basis of AAP-induced OC symptoms.
Purpose of the Study:
- To investigate the association between polymorphisms in the glutamate transporter gene SLC1A1 and AAP-induced OC symptoms in schizophrenia patients.
- To identify potential genetic markers for susceptibility to these adverse effects.
Main Methods:
- A pharmacogenetic case-control association study was conducted.
- Patients with schizophrenia receiving AAP treatment were analyzed (n=94).
- Allele, genotype, and haplotype frequencies of SLC1A1 were assessed using logistic regression.
Main Results:
- Trends of association were observed for specific SNPs (rs2228622, rs3780412) in the SLC1A1 gene.
- A significant association was found for the A/C/G haplotype (rs2228622-rs3780413-rs3780412) with AAP-induced OC symptoms, which withstood multiple testing correction.
- The odds ratio for the associated haplotype was 3.955.
Conclusions:
- Sequence variations in SLC1A1 are associated with susceptibility to AAP-induced OC symptoms.
- This is the first pharmacogenetic study to demonstrate this association.
- Findings suggest the involvement of glutamatergic neurotransmission in the development of AAP-induced OC symptoms.
Related Concept Videos
Obsessive-Compulsive Disorder
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
Antipsychotic Drugs: Typical and Atypical Agents
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...

